Clinical trial · Observational
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to compare the overall survival adjusted to quality of life of 2 groups of patients with multiple myeloma, depending on the type of care: (1) day hospitalization exclusively or (2) day hospitalization combined with hospital-at-home. As secondary objectives, the study aims to compare the impacts of the two types of care organization on: * the survival of patients and response to treatments according to criteria of the International Myeloma Working Group, * psychological status of patients, * specific toxicity related to treatment used (haematological and infectious toxicity, neurotoxicity, ...), * health outcomes, * the caregiver's burden, This study is combined with a qualitative study about the incentives and the barriers, and in order to set up the patient's typology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Association of day hospitalization with hospital-at-home | Other | — | UNRESOLVED |
| Day hospitalization exclusively | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Association of day hospitalization with hospital-at-home
- description
- Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
- interventionNames
- Other: Association of day hospitalization with hospital-at-home
- label
- Day hospitalization exclusively
- description
- Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
- interventionNames
- Other: Day hospitalization exclusively
Primary outcomes (2)
- measure
- Change in Quality of life using questionnaires EORTC QLQ-30
- timeFrame
- At baseline, at the 6th month and the 12th month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patient \> 65 years; * Resident of the departments in Île-de-France region (75, 92, 93 and 94); * Symptomatic multiple myeloma (relapsed or no); * Patient planned to receive one of the following chemotherapy protocols including bortezomib (VELCADE®): VMP (Velcade, Melphalan, Prednisone), VCD (Velcade, Cyclophosphamide, Dexamethasone), VelDex (Velcade, Dexamethasone), VRD (Velcade, Revlimid, Dexamethasone); * Ineligible for autologous hematopoietic stem-cell transplantation (ASCT); * Covered by a health insurance; * Patient who does not oppose to the use of his/her medical data for the purpose of clinical research. * Adult patients under guardianship will can be enrolled in the study, a consent of tutor is needed completed by patient's consent. Exclusion Criteria: * Resident of the departments of 77, 78 and 91 in Île-de-France region; * Asymptomatic myeloma; * Life expectancy \< 6 months; * Patient does not understand French language.
References
Publications (0)
Data not yet available